Loading…

DocMorris LtdDOCM.SWCompetitor analysis, valuation and peers

Switzerland · CHF·Health Care›Medical Distributors
Momentum leader 100
Mkt cap
$1.08B
US dollars, full cap
Free float
70%
of shares outstanding
$/day
$8.75M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-19.4 pp
WACC 6.7%
Hurdle
n/a
no reverse DCF
Next earnings
120 days
18 Mar 2027
Close · CHFCHF 18.00
1D-0.9%
1W-4.0%
1M+13.8%
3M+80.8%
6M+168.7%
YTD+202.5%
1Y+249.2%
ATR %4.6%
52w lowhigh7.7% off high

What DocMorris does

Employees: 1,418

DocMorris at a glance

Size DocMorris (DOCM.SW) is a Switzerland Health Care company (Medical Distributors) with a market value of $1.08B, the 117th largest of 155 Switzerland companies the cockpit tracks. Shares closed at CHF 18.00 on 18 Nov 2026.

Performance Over six months the shares gained 168.7%, against -3.7% for the median peer and +9.3% for the Switzerland market (cap-weighted) — highest of 21 in its peer set.

Growth Revenue grew 10.6% over the last twelve months (peer median +5.0%); the operating margin is -7.5% (peer median 2.8%).

Valuation It trades at 1.0× enterprise value to sales against a peer median of 0.7× (10th most expensive of 21).

Capital Return on invested capital runs 19.4 points below its cost of capital (6.7% WACC).

Credit DocMorris has 1 bond outstanding ($240M).

Next results Next results expected around 18 Mar 2027 (exchange calendar; dates can move).

Relative performance

10020021 May 202621 Aug 202618 Nov 2026DOCM.SW 267Peer median 96
Six months, rebased to 100: DocMorris against the median of its 20 peers (local-currency closes).

DocMorris financials

Reported figures in CHF; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenuen/aCHF 1.12BCHF 1.02BCHF 969MCHF 931M
Revenue growth—+11%+5%+4%—
Gross profitn/aCHF 106MCHF 71.1MCHF 51.1MCHF 6.85M
EBITDAn/a-CHF 39.4M-CHF 45.9M-CHF 32.4M-CHF 98.9M
Net incomen/a-CHF 134M-CHF 97.3M-CHF 114M-CHF 170M
Free cash flown/a-CHF 90.0M-CHF 27.8M-CHF 92.3M-CHF 110M
Capital expendituren/aCHF 27.3MCHF 28.6MCHF 27.7MCHF 46.6M
Total debtn/aCHF 289MCHF 312MCHF 331MCHF 529M

Quarterly statements and history in the cockpit →

DocMorris competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%+100%+150%0%+20%3015847476600587600713603368ARJO-BENTERO68263360NEURDC600628301370008930605136DOCM.SW6-month return →1-month return →
Up and to the right = strong over both horizons. DocMorris is the large dot.

Fundamentals: revenue growth against valuation

-10%0%+10%+20%0×1×2×3015847476600587600713603368ARJO-BENTERO68263360NEURDC8129600628301370008930605136603716ASKERDOCM.SWRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. DocMorris is the large dot.

DocMorris competitors and peer comparison

How DocMorris compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

DocMorris against its 20 peers (data as of 18 Nov 2026)
MeasureDOCM.SWPeer medianRank in peer set
1-month return+13.8%-0.4%4th highest of 21
6-month return+168.7%-3.7%highest of 21
Distance from 52-week high-7.7%-20.2%4th highest of 21
Revenue growth (TTM)+10.6%+5.0%4th highest of 21
Operating margin-7.5%2.8%2nd lowest of 21
EV / Sales1.0×0.7×10th most expensive of 21
ROIC minus cost of capital-19.4 pp+0.6 pplowest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
DocMorris DOCM.SWSwitzerland$1.08B+169%+11%-8%1.0×n/an/a
Shanghai C and D INNOSTIC Medical Technology 301584.SZChina$1.06B-33%+8%3%0.5×-2.7%+17.9%
AS ONE 7476.TJapan$1.10B+25%+10%12%1.3×0.0%+6.3%
Shinva Medical Instrument 600587.SSChina$1.10B-10%+6%5%0.6×-6.9%+1.2%
Nanjing Pharmaceutical 600713.SSChina$999M-2%+3%2%0.3×n/an/a
Guangxi LiuYao 603368.SSChina$975M+1%+2%5%0.4×-9.7%+6.0%
Arjo ARJO-B.STSweden$974M+42%0%8%1.3×-1.0%+3.9%
Entero Healthcare Solutions ENTERO.NSIndia$925M+60%+35%4%1.2×24.7%+29.9%
Shanghai Haohai Biological Technology 6826.HKHong Kong$897M-24%-5%-2%1.9×17.0%+12.4%
Ship Healthcare 3360.TJapan$1.38B+19%+6%3%0.2×-14.5%+7.6%
Neuca NEU.WAPoland$795M-9%+8%2%0.3×5.3%+8.1%
Redcare Pharmacy RDC.DEGermany$1.50B+53%+19%0%0.5×n/an/a
Toho 8129.TJapan$1.64B-5%+4%1%0.1×-4.6%+5.1%
Arata 2733.TJapan$576M-3%+3%1%0.1×-6.2%+3.8%
Shanghai New World 600628.SSChina$573M-10%-2%6%2.1×-1.6%+1.0%
GKHT Medical Technology 301370.SZChina$525M-24%-11%1%0.7×13.1%+7.5%
Suzuken 9987.TJapan$2.36B+8%+5%1%0.1×-10.4%+3.2%
Hanmi Science 008930.KSSouth Korea$2.58B+48%+6%4%2.5×26.0%+9.6%
Shanghai Lily & Beauty Cosmetics 605136.SSChina$449M-28%+5%2%1.1×21.1%-18.1%
Thalys Medical Technology 603716.SSChina$446M-33%-43%-18%4.3×n/an/a
Asker Healthcare ASKER.STSweden$2.69B-14%+12%7%1.8×4.7%+12.7%

DocMorris bonds and credit

DocMorris has 1 bond outstanding with $240M face value.

Every bond, yield and spread in the cockpit →

Questions

Which companies are DocMorris's closest peers?
The cockpit's peer set: Shanghai C and D INNOSTIC Medical Technology (301584.SZ), AS ONE (7476.T), Shinva Medical Instrument (600587.SS), Nanjing Pharmaceutical (600713.SS), Guangxi LiuYao (603368.SS), Arjo (ARJO-B.ST), Entero Healthcare Solutions (ENTERO.NS), Shanghai Haohai Biological Technology (6826.HK).
Is DocMorris expensive compared with its peers?
On ev / sales it trades at 1.0× against a peer median of 0.7×, 10th most expensive of 21 in its peer set.
How has DocMorris stock performed?
Over six months to 18 Nov 2026 the shares returned +168.7% against -3.7% for the median peer; over one year +249.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.